Kyverna Therapeutics, Inc

KYTXNASDAQ · Biological Products, (No Diagnostic Substances)

Financing

SEC filings to 2026-10-05 · every row opens its filing

Shares on issue

61.6M

on 2026-06-30, from 43.1M on 2024-03-31 10-Q ↗

a raise that quarter, at its price

Newest

$300.0M

S-3 of 2026-03-26. 1 prospectus supplement filed under it since. S-3 ↗

$100.0M

Jefferies, agreement of 2026-04-02. No at-the-market sales statement read from a 10-Q or 10-K. 424B5 ↗

Warrants

The 10-Q filed 2026-08-11 is not read yet.

Cash

5 quarters

$199.4M on 2026-06-30 ÷ $39.7M a quarter of operating cash used, the average of four quarters. 10-Q ↗

Raised
Date	What	Shares	Price	Gross	Filing
2025-12-18	Public offering	13,333,333	$7.50	$100.0M	424B5 ↗

Also on file: $40.0M term loan, 2025-10-31 8-K ↗ · up to $150.0M term loan agreed 2025-11-03 8-K ↗